CT 112 - Nuo Therapeutics

Drug Profile

CT 112 - Nuo Therapeutics

Alternative Names: CT-112-Curative-Health-Services; Platelet-factor-4-peptide-CT-112

Latest Information Update: 13 Apr 2016

Price : $50

At a glance

  • Originator Curative Health Services
  • Developer Nuo Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Peptides
  • Mechanism of Action Angiogenesis inhibitors; CXCR3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Inflammation

Most Recent Events

  • 16 Nov 2014 No development reported - Preclinical for Autoimmune disorders in USA (PO)
  • 16 Nov 2014 No development reported - Preclinical for Inflammation in USA (PO)
  • 16 Nov 2014 No development reported - Preclinical for Inflammation in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top